Scpharmaceutical Stock Price, News & Analysis

scPharmaceuticals Inc. (SCPH) has launched FUROSCIX®, the first self-administered subcutaneous loop diuretic for chronic heart failure treatment, effective February 20, 2023. The company ended Q4 2022 with $118.4 million in cash and reported a net loss of $9.2 million for the quarter. This represents an increase from $7.3 million in Q4 2021. The company also completed a $50 million stock offering and a $100 million secured debt financing to support FUROSCIX commercialization. Expectations indicate rising operational costs in 2023 for marketing efforts. CEO John Tucker expressed optimism regarding FUROSCIX's potential impact on patient care.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call scheduled for March 22, 2023, at 4:30 p.m. ET to discuss its fourth quarter 2022 financial results and provide a business update. The call will be accessible via telephone and an audio webcast. The company focuses on developing innovative pharmaceuticals aimed at reducing healthcare costs and improving patient outcomes, specifically targeting outpatient care for acute conditions such as heart failure and infectious diseases.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on March 8 at 10:30 am ET in Boston. This event will highlight the company's focus on developing and commercializing products aimed at optimizing the delivery of infused therapies and improving patient care while reducing healthcare costs. Tucker will also meet with investors from March 6 to 8. A live webcast of the chat will be available on the company's website under the Investor Relations section.

scPharmaceuticals Inc. (Nasdaq: SCPH) has announced the commercial launch of FUROSCIX®, a proprietary formulation of furosemide for treating congestion in patients with NYHA Class II and III chronic heart failure. This product allows for outpatient management through an on-body infusor, delivering an 80-mg dose. The CEO, John Tucker, emphasized the potential for FUROSCIX to reduce hospital admissions and save healthcare costs. Safety information indicates contraindications and possible adverse reactions during therapy. An earnings call in March will provide further updates on this initiative and other developments.

On February 1, 2023, scPharmaceuticals (Nasdaq: SCPH) announced the granting of stock options to 38 new employees, totaling 142,500 shares. The options are part of the Inducement Plan, following Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing talent acquisition. Each option has an exercise price of $6.84 and vests over four years, with 25% vesting after the first year and the remainder in monthly installments. The company focuses on developing solutions to improve healthcare outcomes and reduce costs, especially in outpatient care for heart failure and infectious diseases.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that John Tucker, its President & CEO, will present virtually at the SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 am ET. During this conference, Tucker will also engage in one-on-one meetings with investors. The company focuses on optimizing infused therapies and reducing healthcare costs, particularly through self-administrable treatments for heart failure and infectious diseases. Headquartered in Burlington, MA, scPharmaceuticals aims to enhance outpatient care while improving health outcomes.

scPharmaceuticals Inc. (Nasdaq: SCPH) plans to commercially launch FUROSCIX (furosemide injection) on February 20, 2023. This product is designed for the outpatient treatment of congestion due to fluid overload in patients with NYHA Class II and III chronic heart failure. The On-Body Infusor will deliver a single dose of 80 mg, and the medication is not for emergency situations. CEO John Tucker notes that Medicare and Medicaid beneficiaries will have access from day one, with discussions ongoing to expand reimbursement coverage. Management will provide detailed updates during the fourth quarter earnings call scheduled for March.